Short-term Effects of Metformin on Cardiac and Peripheral Blood Cells Following Cecal Ligation and Puncture-induced Sepsis

Abstract

Aim of the study Sepsis has well-documented inflammatory effects on cardiovascular and blood cells. This study is designed to investigate potential anti-inflammatory effects of metformin on cardiac and blood cells 12 and 24 h following cecal ligation and puncture (CLP)-induced sepsis.

Methods For the purpose of this study, 36 male Wistar rats were divided into six groups: two groups underwent CLP, two groups underwent CLP and received metformin, and two groups only received sham operations. 12 h later, 18 rats (half of rats in each of the three aforementioned groups) were sacrificed and cardiac and blood cells were harvested. Subsequently, 12 h later, the rest of the rats were euthanatized. In all harvested blood and cardiac cells, oxidative stress indicators, antioxidant properties, count of blood cells, neutrophil infiltration, percentage of weight loss and pathological assessment were conducted.

Results In our experiment, metformin elevated antioxidant levels, improved function of blood cells and percentage of weight loss. Moreover, in the groups which received metformin, oxidative stress and neutrophil infiltration markers were decreased significantly. Moreover, pathological investigations of cardiac cell injury were reduced in the metformin group.

Conclusions Our findings suggest that in CLP induced sepsis model, metformin can improve the function of blood and cardiac cells through alleviating inflammation, improvement of anti-inflammation properties, and enhancement of blood profile, and all these effects are more pronounced after 24 h in comparison with 12 h after induction of sepsis.

Key words

inflammation - cardiovascular pharmacology - antidiabetic drugs - drug research

Publication History

Article published online:
21 December 2020

• References

• 1 Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. Intensive Care Medicine 2018; 44: p 925-928
• 2 Fleischmann C. et al. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir Crit Care Med 2016; 193: p 259-272
• 3 Tsolaki V. et al. Sepsis-induced cardiomyopathy: Oxidative implications in the initiation and resolution of the damage. Oxid Med Cell Longev 2017; 2017: p 7393525
• 4 Parrillo JE. et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Annals of Internal Medicine 1990; 113: p 227-242
• 5 Galley HF. Oxidative stress and mitochondrial dysfunction in sepsis. British Journal of Anaesthesia 2011; 107: p 57-64
• 6 Sato R, Nasu M. A review of sepsis-induced cardiomyopathy. J Intensive Care 2015; 3: p 48
• 7 Fattahi F, Ward PA. Complement and sepsis-induced heart dysfunction. Mol Immunol 2017; 84: p 57-64
• 8 Park J. et al. Impact of Metformin Use on Lactate Kinetics in Patients with Severe Sepsis and Septic Shock. Shock 2017; 47: p 582-587
• 9 Ghavimi H. et al. Metformin-attenuated sepsis-induced oxidative damages: a novel role for metformin. Iran J Basic Med Sci 2018; 21: p 469-475
• 10 Tang G. et al. Metformin ameliorates sepsis-induced brain injury by inhibiting apoptosis, oxidative stress and neuroinflammation via the PI3K/Akt Signaling Pathway. Oncotarget 2017; 8: p 97977-97989
• 11 Vaez H. et al. AMPK activation by metformin inhibits local innate immune responses in the isolated rat heart by suppression of TLR 4-related pathway. Int Immunopharmacol 2016; 40: p 501-507
• 12 Vaez H. et al. Metformin Alleviates Lipopolysaccharide-induced Acute Lung Injury through Suppressing Toll-like Receptor 4 Signaling. Iran J Allergy Asthma Immunol 2016; 15: p 498-507
• 13 Vaez H. et al. Cardioprotective effect of metformin in lipopolysaccharide-induced sepsis via suppression of toll-like receptor 4 (TLR4) in heart. Eur J Pharmacol 2016; 772: p 115-123
• 14 Shrum B. et al. A robust scoring system to evaluate sepsis severity in an animal model. BMC Research Notes 2014; 7: p 1-13
• 15 Hassani S. et al. Alteration of hepatocellular antioxidant gene expression pattern and biomarkers of oxidative damage in diazinon-induced acute toxicity in Wistar rat: a time-course mechanistic study. EXCLI Journal 2018; 17: p 57
• 16 Nili-Ahmadabadi A. et al. Thymoquinone attenuates hepatotoxicity and oxidative damage caused by diazinon: an in vivo study. Research in Pharmaceutical Sciences 2018; 13: p 500
• 17 Armstrong D, Browne R. The analysis of free radicals, lipid peroxides, antioxidant enzymes and compounds related to oxidative stress as applied to the clinical chemistry laboratory. Adv Exp Med Biol 1994; 366: p 43-58
• 18 Benzie IFF, Strain JJ. The Ferric Reducing Ability of Plasma (FRAP) as a Measure of “Antioxidant Power”: The FRAP Assay. Analytical Biochemistry 1996; 239: p 70-76
• 19 ML H. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994; 233: p 380-385
• 20 Ghazanfari G. et al. Biochemical and histopathological evidences for beneficial effects of Satureja Khuzestanica Jamzad essential oil on the mouse model of inflammatory bowel diseases. Toxicology Mechanisms and Methods 2006; 16: p 365-372
• 21 Harchegani AL. et al. Cromolyn sodium attenuates paraquat-induced lung injury by modulation of proinflammatory cytokines. Drug Research 2017; 67: p 283-288
• 22 Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets—an updated view. Mediators of Inflammation 2013; 2013
• 23 Yu Y, Tang D, Kang R. Oxidative stress-mediated HMGB1 biology. Frontiers in Physiology 2015; 6: p 93
• 24 Abdulmahdi W. et al. HMGB1 redox during sepsis. Redox Biology 2017; 13: p 600-607
• 25 Yang H. et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101: p 296-301
• 26 Wang D, Yin Y, Yao Y. Advances in sepsis-associated liver dysfunction. Burns & Trauma 2014; 2: p 97
• 27 Ahmad A, Druzhyna N, Szabo C. Delayed treatment with sodium hydrosulfide improves regional blood flow and alleviates cecal ligation and puncture (CLP)-induced septic shock. Shock (Augusta, Ga.) 2016; 46: p 183
• 28 Tzanavari T. et al. Metformin protects against infection-induced myocardial dysfunction. Metabolism 2016; 65: p 1447-1458
• 29 Vaez H. et al. AMPK activation by metformin inhibits local innate immune responses in the isolated rat heart by suppression of TLR 4-related pathway. International Immunopharmacology 2016; 40: p 501-507
• 30 Yang Y. et al. Liver Kinase B1/AMP-Activated Protein Kinase Pathway Activation Attenuated the Progression of Endotoxemia in the Diabetic Mice. Cellular Physiology and Biochemistry 2017; 42: p 761-779
• 31 Granger JI. et al. Sepsis-induced morbidity in mice: effects on body temperature, body weight, cage activity, social behavior and cytokines in brain. Psychoneuroendocrinology 2013; 38: p 1047-1057
• 32 Zhang X. et al. The alleviative effects of metformin for lipopolysaccharide-induced acute lung injury rat model and its underlying mechanism. Saudi Pharm J 2017; 25: p 666-670
• 33 Cheng S-C. et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nature Immunology 2016; 17: p 406
• 34 Kim J. et al. Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction. Journal of Biological Chemistry 2014; 289: p 23246-23255
• 35 Tsoyi K. et al. Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. British Journal of Pharmacology 2011; 162: p 1498-1508
• 36 Liu Z. et al. AMP-activated protein kinase and Glycogen Synthase Kinase 3β modulate the severity of sepsis-induced lung injury. Molecular Medicine 2015; 21: p 937-950
• 37 Tang G. et al. Metformin ameliorates sepsis-induced brain injury by inhibiting apoptosis, oxidative stress and neuroinflammation via the PI3K/Akt signaling pathway. Oncotarget 2017; 8: p 97977
• 38 Vaez H. et al. Cardioprotective effect of metformin in lipopolysaccharide-induced sepsis via suppression of toll-like receptor 4 (TLR4) in heart. European Journal of Pharmacology 2016; 772: p 115-123
• 39 Ezgi K. et al. Early Treatment with Metformin Decreases Pancreatic Damage in Rats with LPS Induced Sepsis. Türk Yaşam Bilimleri Dergisi 3: p 194-199
• 40 Ghavimi H. et al. Metformin-attenuated sepsis-induced oxidative damages: a novel role for metformin. Iranian Journal of Basic Medical Sciences 2018; 21: p 469
• 41 Kumar S. et al. Evaluation of oxidative stress and antioxidant status: Correlation with the severity of sepsis. Scandinavian Journal of Immunology 2018; 87: p e12653
• 42 Rinaldi S, Landucci F, De AR. Gaudio, Antioxidant therapy in critically septic patients. Curr Drug Targets 2009; 10: p 872-880
• 43 Markowicz-Piasecka M. et al. Metformin–a future therapy for neurodegenerative diseases. Pharmaceutical Research 2017; 34: p 2614-2627
• 44 Diniz Vilela D. et al. The role of metformin in controlling oxidative stress in muscle of diabetic rats. Oxidative Medicine and Cellular Longevity 2016; 2016
• 45 Sadaka F. Red blood cell transfusion in sepsis: a review. J Blood Disord Transfus S 2012; 4: p 2
• 46 Can E, Hamilcikan Ş, Can C. The Value of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio for Detecting Early-onset Neonatal Sepsis. Journal of Pediatric Hematology/Oncology 2018; 40: p e229-e232
• 47 Muady GF. et al. Hemoglobin levels and blood transfusion in patients with sepsis in Internal Medicine Departments. BMC Infectious Diseases 2016; 16: p 569
• 48 Ferreira FB. et al. Glucose homeostasis in two degrees of sepsis lethality induced by caecum ligation and puncture in mice. International Journal of Experimental Pathology 2017; 98: p 329-340
• 49 Dong L-W. et al. Transcriptional regulation of α1-adrenoceptor gene in the rat liver during different phases of sepsis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1999; 1453: p 207-215